Blood advances first decision
WebDec 5, 2024 · Early in the pandemic, reports emerged that patients with active or resolved cancers may be at particularly high risk of adverse outcomes from COVID-19. 3 This finding was especially concerning to patients with hematologic malignancies and those providing care for them and potentially affected shared management decision making. … WebBlood Advances requires research papers, specifically Regular Articles, to include 1 to 2 key points. The purpose of these short, bullet-pointed statements is to identify the most relevant outcomes of the paper and to provide a synopsis encapsulating the significance of the research and its implications for readers.
Blood advances first decision
Did you know?
WebRevised manuscripts should be received within 3 months of the date on the initial decision e-mail or they will be considered as a new submission, with a separate manuscript number and submission fee. WebApr 11, 2024 · Outcomes after biochemical or clinical progression in patients with multiple myeloma. This article from Goldman-Mazur and colleagues is a large retrospective data analysis of patterns of relapse postinduction therapy for newly diagnosed multiple … First Edition. Research Article April 10 2024. ... Advertising in Blood Advances; … Author Guide Contents of Blood Advances Author Guide. Journal Scope – For … Improving eligibility criteria for first-line trials for patients with DLBCL using a US … American Society of Hematology; 2024 L Street NW, Suite 900; Washington, DC … Blood Advances publishes more peer-reviewed hematology research than any … Phylogenetic network showing the evolutionary relationships among ABO …
WebSep 28, 2024 · Decision aids may be useful in helping individuals make decisions consistent with their individual risks, values, and preferences. ... The first allogeneic transplantation for SCD was reported in 1984 in a pediatric patient with SCD and acute myelogenous leukemia, ... The guideline was then subjected to peer review by Blood … WebJun 19, 2024 · The panel selected outcomes of interest for each question a priori, following the approach described in detail elsewhere. 24 In brief, the panel first brainstormed all possible outcomes before rating their relative importance for decision making following the GRADE approach. 24 While acknowledging considerable variation in the impact on …
WebJan 20, 2024 · Justyne E. Ross, Bing M. Zhang, Kristy Lee, Shruthi Mohan, Brian R. Branchford, Paul Bray, Stefanie N. Dugan, Kathleen Freson, Paula G. Heller, Walter H. A. Kahr, Michele P. Lambert, Lori Luchtman-Jones, Minjie Luo, Juliana Perez Botero, Matthew T. Rondina, Gabriella Ryan, Sarah Westbury, Wolfgang Bergmeier, Jorge Di Paola; on … WebOct 29, 2024 · In addition to its hypothesis-generating role, being able to predict such key genomic alterations based off readily available data may play a role in upfront decision making in patients with myeloid malignancies, as the presence of certain mutations such as TP53, IDH1, and SF3B1 has established prognostic and therapeutic ramifications. …
WebThe Editors select reviewers and make the final decision on the manuscript. Reviewers remain unknown to the authors. ... Authors of work reviewed by broad-scope journals are strongly encouraged to first send a presubmission inquiry to ... Are the results sufficiently important and novel to advance the field? Blood cannot publish articles that ...
WebEditorial Policies for Authors – For detailed descriptions of Blood Advances ' policies regarding: authorship criteria conflict of interest disclosure originality publication of medical research involving human subjects data sharing, distribution of reagents, and compound structure disclosure deposition into public databases chicken in cartoonWebMar 13, 2024 · If your manuscript is sent to reviewers, please share with the community how many days the evaluated process took by editor's office (not include the evaluated process of reviewers). Based on the Blood Advances Review Speed Feedback System, it takes authors - days to get the first editorial decision. google stock option chainWebNov 16, 2024 · Acute myeloid leukemia (AML) remains a difficult disease to treat with a limited proportion of patients having long-term cures, despite several recently US Food and Drug Administration–approved therapies. 1 T cells can be used to eradicate leukemia as evident by grafted allogeneic T cells vs leukemia effected seen in postallogeneic stem … chicken in can recipeWebDec 6, 2024 · The American Board of Internal Medicine has identified blood transfusion as the most frequent and overused therapeutic intervention in the United States. 1 To curtail inappropriate transfusions, accreditation agencies such as The Joint Commission have proposed performance indicators in patient blood management (PBM) to promote … chicken in capes and slippersWebJan 12, 2024 · For patients with a high probability of VWD (eg, affected first-degree relative), the panel recommends against relying on a BAT to decide whether to order specific blood testing (strong recommendation based on moderate certainty in the evidence from diagnostic accuracy studies ⊕⊕⊕ ). Remarks: chickeninc bojong indahWebBlood Advances may delay First Edition publication temporarily for reasons such as promotional efforts (e.g., an American Society of Hematology press release). The corresponding author (s) will be notified if an article is being held for such a reason. Authors may also request a delay, but please notify journal staff as soon as possible to ... chicken in cashew nutsWebNov 10, 2024 · An ISTH consensus statement previously suggested that it may be safe to discontinue anticoagulation if the risk of recurrent VTE is predicted to be less than 5% (with an upper bound of the 95% CI of 8%) at 1 year after discontinuation, 41 whereas studies aimed at deriving and validating clinical decision tools have sought to identify groups ... google stock portfolio tracker